MPM Bioimpact is an SEC-registered investment adviser based in Boston, MA that reports managing 3 hedge funds on Form ADV. It reports $3.6 billion in regulatory assets under management. Its private funds, of all types, hold $3.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +50.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +91.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $3.6 billionForm ADV Item 5.F
- Gross assets of private funds
- $3.5 billionAll private fund types, Form ADV
- Hedge funds managed
- 314 private funds in total
- Employees
- 50Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 148467
- Latest Form ADV
- 04/28/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +30.9% | +14.8% |
| Q1 2026 | +14.7% | -4.6% |
| Q4 2025 | +43.8% | +2.4% |
| Q3 2025 | +19.9% | +7.8% |
| Q2 2025 | +2.4% | +10.4% |
| Q1 2025 | -17.0% | -4.5% |
| Q4 2024 | -13.9% | +2.1% |
| Q3 2024 | +0.9% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 36 share positions ($1,299,078,595) reported by MPM Bioimpact LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Cullinan Therapeutics Inc11.49%
- Aktis Oncology Inc7.25%
- Travere Therapeutics Inc4.93%
- Edgewise Therapeutics Inc4.93%
- Dyne Therapeutics Inc3.98%
- Corcept Therapeutics Inc3.74%
- Relay Therapeutics Inc3.29%
- Trevi Therapeutics Inc3.28%
- Iovance Biotherapeutics Inc3.23%
- Liquidia Corporation3.13%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Cullinan Therapeutics Inc | $149,218,593 | 11.49% | 9,721,081 | -0.11% |
| Aktis Oncology Inc | $94,154,428 | 7.25% | 4,835,872 | Unchanged |
| Travere Therapeutics Inc | $64,082,813 | 4.93% | 1,088,363 | -3.06% |
| Edgewise Therapeutics Inc | $63,985,072 | 4.93% | 1,575,987 | -2.76% |
| Dyne Therapeutics Inc | $51,683,232 | 3.98% | 3,208,146 | +66.91% |
| Corcept Therapeutics Inc | $48,627,060 | 3.74% | 422,000 | -45.27% |
| Relay Therapeutics Inc | $42,770,883 | 3.29% | 2,369,578 | -1.91% |
| Trevi Therapeutics Inc | $42,657,934 | 3.28% | 2,978,906 | -3.08% |
| Iovance Biotherapeutics Inc | $42,025,578 | 3.23% | 2,835,734 | New |
| Liquidia Corporation | $40,630,495 | 3.13% | 1,342,713 | -3.14% |
| Natera Inc | $37,439,686 | 2.88% | 90,585 | -2.22% |
| Urogen Pharma LTD | $36,960,745 | 2.85% | 909,691 | -2.54% |
| Immunocore Hldgs PLC | $36,447,624 | 2.81% | 1,203,289 | New |
| DBV Technologies S A | $35,805,190 | 2.76% | 3,044,659 | -16.96% |
| Taysha Gene Therapies Inc | $35,370,610 | 2.72% | 7,262,959 | +61.40% |
| Abivax SA | $32,516,089 | 2.50% | 328,379 | -2.37% |
| Vir Biotechnology Inc | $31,412,569 | 2.42% | 2,809,711 | New |
| Adlai Nortye LTD | $31,305,888 | 2.41% | 1,956,618 | +1.05% |
| Verastem Inc | $31,005,412 | 2.39% | 3,851,604 | New |
| Uniqure NV | $29,026,138 | 2.23% | 1,201,413 | -1.99% |
| Odyssey Therapeutics Inc | $28,643,602 | 2.20% | 1,289,091 | New |
| Tarsus Pharmaceuticals Inc | $27,723,860 | 2.13% | 352,676 | +9.52% |
| Palvella Therapeutics Inc Ne | $27,259,520 | 2.10% | 197,633 | -3.13% |
| Aclaris Therapeutics Inc | $27,236,948 | 2.10% | 5,178,127 | +396.72% |
| Oruka Therapeutics Inc | $24,987,000 | 1.92% | 300,000 | New |
| Oric Pharmaceuticals Inc | $24,541,680 | 1.89% | 1,821,951 | -3.20% |
| Stoke Therapeutics Inc | $24,053,458 | 1.85% | 925,133 | +27.90% |
| Belite Bio Inc | $22,651,780 | 1.74% | 133,387 | -2.78% |
| Neurogene Inc | $21,472,561 | 1.65% | 771,839 | New |
| Zura Bio LTD | $18,510,631 | 1.42% | 4,449,671 | -0.52% |
| Annexon Inc | $18,149,306 | 1.40% | 4,290,616 | +21.05% |
| Monte Rosa Therapeutics Inc | $13,423,827 | 1.03% | 1,125,216 | -3.09% |
| Bioage Labs Inc | $13,164,343 | 1.01% | 1,856,748 | +11.34% |
| Corbus Pharmaceuticals Hldgs | $11,370,795 | 0.88% | 1,667,272 | New |
| Bright Minds Biosciences Inc | $9,748,230 | 0.75% | 195,669 | -3.19% |
| First Tracks Biotherapeutics | $9,015,015 | 0.69% | 254,374 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 9 new positions, 10 sold out, 8 increased, 18 reduced and 1 unchanged.
Number of positions (a count, not dollars)
- New positions9
- Increased8
- Unchanged1
- Reduced18
- Sold out10
New positions
| Stock | Value | Shares |
|---|---|---|
| Iovance Biotherapeutics Inc | $42,025,578 | 2,835,734 |
| Immunocore Hldgs PLC | $36,447,624 | 1,203,289 |
| Vir Biotechnology Inc | $31,412,569 | 2,809,711 |
| Verastem Inc | $31,005,412 | 3,851,604 |
| Odyssey Therapeutics Inc | $28,643,602 | 1,289,091 |
| Oruka Therapeutics Inc | $24,987,000 | 300,000 |
| Neurogene Inc | $21,472,561 | 771,839 |
| Corbus Pharmaceuticals Hldgs | $11,370,795 | 1,667,272 |
| First Tracks Biotherapeutics | $9,015,015 | 254,374 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Revolution Medicines Inc | $92,232,216 | 492,483 |
| Alumis Inc | $56,815,223 | 2,019,020 |
| Ultragenyx Pharmaceutical In | $47,354,199 | 1,418,215 |
| Dianthus Therapeutics Inc | $40,941,795 | 420,002 |
| Moonlake Immunotherapeutics | $31,287,647 | 1,606,967 |
| Syndax Pharmaceuticals Inc | $29,150,813 | 1,333,523 |
| Forte Biosciences Inc | $20,983,270 | 987,448 |
| Entrada Therapeutics Inc | $9,222,470 | 1,253,053 |
| Context Therapeutics Inc | $719,542 | 1,299,046 |
| Werewolf Therapeutics Inc | $28,851 | 80,142 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Aclaris Therapeutics Inc | +4,135,660 | +396.72% | $27,236,948 | 5,178,127 |
| Dyne Therapeutics Inc | +1,286,053 | +66.91% | $51,683,232 | 3,208,146 |
| Taysha Gene Therapies Inc | +2,762,959 | +61.40% | $35,370,610 | 7,262,959 |
| Stoke Therapeutics Inc | +201,819 | +27.90% | $24,053,458 | 925,133 |
| Annexon Inc | +746,262 | +21.05% | $18,149,306 | 4,290,616 |
| Tarsus Pharmaceuticals Inc | +30,669 | +9.52% | $27,723,860 | 352,676 |
| Bioage Labs Inc | +189,087 | +11.34% | $13,164,343 | 1,856,748 |
| Adlai Nortye LTD | +20,327 | +1.05% | $31,305,888 | 1,956,618 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Corcept Therapeutics Inc | -349,028 | -45.27% | $48,627,060 | 422,000 |
| DBV Technologies S A | -621,625 | -16.96% | $35,805,190 | 3,044,659 |
| Travere Therapeutics Inc | -34,368 | -3.06% | $64,082,813 | 1,088,363 |
| Edgewise Therapeutics Inc | -44,793 | -2.76% | $63,985,072 | 1,575,987 |
| Trevi Therapeutics Inc | -94,671 | -3.08% | $42,657,934 | 2,978,906 |
| Liquidia Corporation | -43,461 | -3.14% | $40,630,495 | 1,342,713 |
| Urogen Pharma LTD | -23,724 | -2.54% | $36,960,745 | 909,691 |
| Palvella Therapeutics Inc Ne | -6,394 | -3.13% | $27,259,520 | 197,633 |
| Natera Inc | -2,053 | -2.22% | $37,439,686 | 90,585 |
| Relay Therapeutics Inc | -46,094 | -1.91% | $42,770,883 | 2,369,578 |
| Oric Pharmaceuticals Inc | -60,211 | -3.20% | $24,541,680 | 1,821,951 |
| Abivax SA | -7,968 | -2.37% | $32,516,089 | 328,379 |
| Belite Bio Inc | -3,821 | -2.78% | $22,651,780 | 133,387 |
| Uniqure NV | -24,442 | -1.99% | $29,026,138 | 1,201,413 |
| Monte Rosa Therapeutics Inc | -35,865 | -3.09% | $13,423,827 | 1,125,216 |
| Bright Minds Biosciences Inc | -6,445 | -3.19% | $9,748,230 | 195,669 |
| Cullinan Therapeutics Inc | -10,260 | -0.11% | $149,218,593 | 9,721,081 |
| Zura Bio LTD | -23,172 | -0.52% | $18,510,631 | 4,449,671 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Forte Biosciences, Inc. | 13G amendment | 0% | 0 | Nov 13, 2026 | SEC.gov ↗ |
| DBV Technologies S.A. | 13G amendment | 4.8% | 15,223,295 | Nov 13, 2026 | SEC.gov ↗ |
| Corbus Pharmaceuticals Holdings, Inc. | 13G | 8.6% | 1,667,272 | Nov 13, 2026 | SEC.gov ↗ |
| Context Therapeutics Inc. | 13G amendment | 1.4% | 1,299,046 | Aug 14, 2026 | SEC.gov ↗ |
| Climb Bio, Inc. | 13G amendment | 0% | 0 | Aug 14, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Aug 14, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (21)
As reported in the adviser's Form ADV filed Jun 26, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures